Broadcast Date: January 25th, 2017
Time: 11:00 am ET, 8:00 am PT
The study of metabolic disease is changing as limitations of classical in vitro cell models are increasingly evident, causing investigators to search for improved alternatives. Induced pluripotent stem cells (iPSCs) are the logical alternative for advancing basic biology and applied biomedical research through the development of relevant human cell models. Recapitulating native physiological behavior is the ideal scenario for phenotypic screening and target identification—techniques that are paramount to both academic and biopharmaceutical researchers.
Join us for this GEN webinar, where we will focus first on developing assays with human iPSC-derived hepatocytes to interrogate insulin signaling and glucose metabolism—and then on implementing these cells into research programs for the study of lipid dysregulation and metabolic disease state and progression.
Who Should Attend
- Drug discovery scientists
- Principal investigators
- Researchers working with hepatocytes
- Scientists interested in phenotypic screening
- Stem cell scientists
- Translational research scientists
You Will Learn
- How human iPSC-derived hepatocytes can be utilized for the study of metabolic functions related to glucose regulation, mitochondrial function, and lipid dysregulation
- How iCell Hepatocytes can overcome the limitations of existing cell models for more relevant hepatic functionality and phenotypic stability
- About a model of fatty liver disease that combines the use of human iPSC-derived hepatocytes with high-content imaging analysis amenable for high-throughput screening
Produced with support from:
Coby B. Carlson, Ph.D.
Strategic Marketing Manager,
Cellular Dynamics International, a FUJIFILM Company
Siobhan Malany, Ph.D.
Director of Translational Biology,
Sanford Burnham Prebys Medical Discovery Institute